GeeGee, I respect your opinion and I'm going to research it more. Will report back.
I don't know how it hits the lungs differently like you mentioned so that's an area I will focus on.
The second part you are assuming we don't need need a high number of cases because of lower P-Value but we simply won't know that until the data is unblinded. We don't know at this point if it has superior efficacy or not.
We only know of 21 patients from a Dr that used to work with Sami Said. And until it's peer reviewed call me skeptical.
OK, Gee Gee you were close. This is my interpretation of the difference between the two synthetic VIP's based on JJ's comments and what I've been able to find so far.
There are two receptors that VIP targets and has 2 different functions.
PHAS version is the one that targets VPAC2. It's a modified peptide that is optimized for VPAC2. This is in the blood vessels and has a vaso dilating effect. This is the same type of VIP used for ED. The original intent is for pulmonary hypertension.
Aviptadil targets VPAC1 that is in the lung.
This difference could explain why you would get different results.
News 
Market Data 
Discover 
AI
